The temptation of the dark side: Genentech, Avastin and macular degeneration
(UPDATED: See below.)
Committing your biotechnology giant to “the best interests of patients [and] the medical profession,” as Genentech CEO Arthur Levinson does on its his company’s Web page, is certainly a fine sentiment. When you subsequently decide to restrict use of a drug used by many… Continue Reading